Foghorn Therapeutics, Inc.

Foghorn Therapeutics, Inc.

Foghorn Therapeutics, Inc.

Overview
Date Founded

2015

Headquarters

100 Binney Street,Suite 610,Cambridge, MA 02142

Type of Company

Public

Employees (Worldwide)

85

Industries

Biotechnology

Company Description

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Foghorn Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial Officer

Chief Scientific Officer

Chief Medical Officer

Chief Legal Officer

Senior Director, Clinical Development Operations

Senior Vice President, People & Organization

Senior Vice President, Business & Operations

Senior Vice President, Drug Discovery

Vice President, Program Leadership

Board of Directors

Founder at Foghorn Therapeutics, Inc.

Member, Editorial Board at Annals of Oncology

President & Chief Executive Officer at Foghorn Therapeutics, Inc.

Chief Scientific Officer at Agios Pharmaceuticals, Inc.

Managing Director at Bain Capital Life Sciences LP

Chief Medical & Scientific Officer at Takeda Pharmaceutical Co., Ltd.

Managing Partner at Flagship Pioneering

President, Chief Executive Officer & Director at Evelo Biosciences, Inc.

Paths to Foghorn Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Foghorn Therapeutics, Inc.
Owners & Shareholders
Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Details Hidden

ADIA US manages a highly diversified portfolio that spans geographies, asset classes and asset types, enabling us to generate consistent, long-term returns throughout market cycles. The firm has a flexible investment approach that combines long-term focus at a portfolio level with an ability to respond quickly to more fleeting opportunities when they arise. Their portfolio comprises more than two dozen asset classes and sub categories, from equities and fixed income to hedge funds, real estate, private equity and infrastructure.

Details Hidden

Invus Public Equities Advisors makes majority investments in private, high growth companies. The firm also takes significant, long-term positions in public companies whose fundamentals and management they believe in. Invus focuses on investments in the stocks of small- to mid-cap companies that are trading below the firm's assessment of their intrinsic business value. The average holding period in their public equity portfolio is measured in years. Invus invests in a variety of industries, including but not limited to, consumer products and services, food, specialty retail, software, biotechnology, medical devices, healthcare products and professional services.

Recent Transactions
Details Hidden

Foghorn Therapeutics, Inc. issued USD Common Stock

Transaction Advisors
Escrow Agent

Advised onFoghorn Therapeutics, Inc. issued USD Common Stock

Underwriter

Advised onFoghorn Therapeutics, Inc. issued USD Common Stock

Auditor

Advised onFoghorn Therapeutics, Inc. issued USD Common Stock

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Key Stats and Financials As of 2019
Market Capitalization
$639M
Total Enterprise Value
Earnings Per Share
$-1.39
Total Equity
$-88M
Total Debt
$103M
EBITDA
$-49.3M
Net Profit
$-51.1M
Revenue
$0
Investors
Details Hidden

Co-Founder at Amplyx Pharmaceuticals, Inc.

Details Hidden

Chief Scientific Officer at PharmaCyte Biotech, Inc.

Details Hidden

Managing Partner at Flagship Pioneering

Suppliers
Stanford University Biotechnology | Redwood City, usa

Stanford University, located between San Francisco and San Jose in the heart of California's Silicon Valley, is one of the world's leading teaching and research universities. Since its opening in 1891, Stanford has been dedicated to finding solutions to big challenges and to preparing students for leadership in a complex world.

Dana-Farber Cancer Institute, Inc. Biotechnology | Boston, MA

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Competitors
Agios Pharmaceuticals, Inc. Pharmaceuticals - Cambridge, Massachusetts

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Foghorn Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Foghorn Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Foghorn Therapeutics, Inc..